ImmunityBio Expands ANKTIVA Commercial Footprint with EU and Saudi Approvals

ImmunityBio expands international commercial footprint with ANKTIVA

ImmunityBio is rapidly broadening ANKTIVA’s global reach after securing European Commission authorization and approvals in the Kingdom of Saudi Arabia, marking regulatory clearance across four jurisdictions in less than two years since its initial U.S. approval. The Saudi authorizations cover two indications, giving the company early clinical and regulatory validation outside the United States and expanding its addressable patient population in strategically important markets. The consecutive approvals reflect a concerted push to move ANKTIVA from a U.S.-centric asset to a multi-jurisdictional commercial product.

The company is using the multi-jurisdiction platform to scale manufacturing, widen distribution channels and begin systematic real-world data collection and post-approval studies. ImmunityBio is positioning these markets to support procurement and reimbursement discussions, local commercial agreements and physician education programs that accelerate clinical adoption. The approvals also enable the firm to aggregate region-specific evidence that could support future label expansions and health-technology assessments.

Strategically, the rapid rollout shortens timelines to market entry and strengthens ImmunityBio’s negotiating position with payors and partners, while creating opportunities to shore up supply-chain resilience and expand patient access. The company is balancing these commercial and operational priorities with regulatory and manufacturing risks inherent in multinational launches, and is planning targeted initiatives to manage market-access challenges as ANKTIVA moves into broader clinical use.

Oncology sector trends emphasize modality diversification

The broader oncology sector is showing accelerated innovation, with more than 2,100 clinical trials initiated globally in 2024 and targeted therapies the fastest-growing subsegment. Development pipelines increasingly include antibody‑drug conjugates, radiopharmaceuticals, cell therapies and device‑based platforms, with over 100 ADCs in active development and companies such as ImmunityBio, Oncolytics, Novocure, Perspective Therapeutics and Nuvation Bio exemplifying the trend.

Researchers at the American Association for Cancer Research predict wider deployment of smarter delivery systems by 2026 — from armored T cells and off‑the‑shelf NK platforms to stromal‑targeting radiopharmaceuticals — and several programs are already converting early signals into registration‑enabling data. Notably, peer Oncolytics recently wins Fast Track status for pelareorep in KRAS‑mutant, microsatellite‑stable metastatic colorectal cancer after data showing a 33% objective response rate and a median overall survival of 27.0 months versus 11.2 months for standard therapy, underscoring rapid progress across novel oncology modalities.